CTRI/2022/04/041694进行中（未招募）未知
A randomized, open label, multi-center, two-treatment, four-period, two-sequence, full replicate crossover, multiple dose, steady state Bioequivalence (BE) study of Pazopanib Tablets at a dose of 800 mg (4*200 mg tablets) of Oncogen Pharma (Malaysia) Sdn. Bhd. with Votrient® (Pazopanib) Tablets at a dose of 800 mg (4*200 mg tablets) of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in advanced renal cell carcinoma patients under fasting condition - NA
Oncogen Pharma Malaysia Sdn Bhd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects will be considered eligible for the study based on the following criteria:
- •1. Willing and able to provide voluntary informed consent and to follow the protocol requirements.
- •2. Subjects aged greater than18 years with BMI at least 17.00 calculated as weight in kg per height in m2.
- •3. Subjects with confirmed diagnosis of advanced renal cell carcinoma includes,
- •(a) Newly diagnosed subjects
- •(b) Subjects who are already receiving stable dose of Pazopanib tablets of 800 mg per day for at least 15 days
- •(c) Subjects with failure of first line treatment for advanced renal cell carcinoma and as per investigators discretion are eligible to receive Pazopanib tablets.
- •4. Subjects able to swallow and retain oral medication
- •5. Life expectancy of at least 3 months at the time of screening.
- •6. Acceptable hematology status:
- •a. Hemoglobin greater than or equal to 9.0 g per dL
- •b. Absolute neutrophil count (ANC) greater than or equal to 1500 cells per mm3
- •c. Platelet count greater than or equal to 100,000 cells per mm3
- •7. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) less than or equal to 2 X ULN (less than or equal to 5 X ULN in case of liver metastasis)
- •b. Aspartate aminotransferase (AST) less than or equal to 2X ULN less than or equal to 5 X ULN in case of livermetastasis)
- •c. Bilirubin less than or equal to ULN
- •8. Subjects with Creatinine clearance greater than or equal to 30 mL per minute
- •9. Cardiac ejection fraction greater than or equal to 50 percent by echocardiogram (ECHO) within 28 days of first dose of Investigational Product.
- •10. Male subjects (including those who had a vasectomy) with female partners of reproductive potential must agree to use condoms from screening, during study and for at least two weeks after treatment discontinuation.
- •11. Female subjects of child bearing potential with negative serum pregnancy test at screening and at Day 1.
- •12. Women of childbearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing acceptable methods of contraception from screening, during study and for at least two weeks after treatment discontinuation.
- •Acceptable methods of contraception are:
- •a. Oral or other (e.g. injection, patch or implant) hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
- •b. Intrauterine device or intrauterine system
- •c. Double barrier method of contraception (Condom and occlusive cap or condom and spermicidal agent)
- •d. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
- •e. Total abstinence, partial abstinence is not acceptable.
- •13. No history of addiction to any recreational drug or drug dependence or alcohol addiction.
排除标准
- •Subjects will be excluded from the study based on the following criteria:
- •1.Known hypersensitivity to Pazopanib or the components of investigational product.
- •2.History or presence of any uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •3.Subjects with hypokalemia, hypomagnesaemia, long QT syndrome (QTc of > 450 msec in male or QTc of > 470 msec in female) or with relevant pre-existing cardiac disease at the time of screening
- •4.Subjects found with major vascular disease, arterial thromboembolic event or VTE in previous 6 months from the screening
- •5.Currently receiving or anticipated to receive any medications or substances that are strong inhibitors or inducers of the CYP3A4, strong inhibitors of P-gp or breast cancer resistance protein (BCRP); narrow therapeutic index drugs that are metabolized by CYP3A4, CYP2D6 or CYP2C8; simvastatin, H2 receptor antagonist and PPIs.(Appendix B)
- •6.Subjects who are receiving or are anticipated to receive anti-coagulant therapy during study participation
- •7.Receiving any drugs known to prolong the QT interval within 4 weeks prior to first IP administration or during the study
- •8.Known central nervous system (CNS) metastasis.
- •9.History or presence of hemoptysis, cerebral hemorrhage, or clinically significant gastrointestinal hemorrhage in the past 6 months
- •10.History or presence of Thrombotic microangiopathy (TMA) or any other dermatological toxicity..
- •11.History or presence of gastrointestinal perforation or fistula
- •12.History or presence of Interstitial Lung Disease/Pneumonitis
- •13.History or presence of Posterior Reversible Encephalopathy Syndrome
- •14.Subjects who are at risk of TLS (e.g. rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration)
- •15.Subjects with ECOG Performance Status of > 2.
- •16.Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •17.Surgical or other non-healing wounds.
- •18.Subjects with positive serology for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency virus (HIV).
- •19.Subjects who tested positive for Coronavirus infection (COVID-19)
- •20.Subjects with current clinical or laboratory evidence of active infection.
- •21.History of other malignancies in the last 5 years
- •22.Have not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), hemoglobin greater than or equal to 9.0 g/dL, fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (as per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0).
- •23.If subjects found positive in urine alcohol test
- •24.If subjects found positive in urine screen for drugs of abuse
- •25.Participation in any clinical study within 90 days before the first dose of Investigational Product.
- •26.Loss of greater than or equal to 350mL (1 unit) of blood within 90 days before enrollment in the study.
- •27.Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subjects to participate in the study including but not limited to cirrhosis or psychiatric i
研究者
相似试验
已完成
1 期
Comparative study of Nilutamide 150 mg tabletCTRI/2018/01/011386Genus Lifesciences Inc40
Unknown
不适用
euprorelin Acetate Injectable Suspension 11.25 mg in male subjects with metastatic prostate cancerCTRI/2019/08/020820Daewoong Pharmaceutical Co Ltd
已完成
4 期
Pharmacokinetic Study of Pazopanib in subjects with Advanced renal cell carcinoma.CTRI/2020/10/028441Torrent Pharmaceuticals Ltd India61
进行中（未招募）
不适用
Bioequivalence study of Olaparib Tablets 150 mg with LYNPARZA�® (Olaparib) tablets 150 mg in male or female patients with ovarian cancer or breast cancer or prostate cancer.CTRI/2021/08/035525atco Pharma Limited
进行中（未招募）
不适用
Multiple dose, steady-state relative bioavailability of Pazopanib 200 mg tablets at a dose of 800 mg (4x200 mg tablets) in subjects with advanced renal cell carcinoma under fasting condition.CTRI/2021/04/032507Oncogen Pharma Malaysia Sdn Bhd15